Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1
This study is the largest clinical study to date utilizing the TSO 500. It provides an opportunity to further characterize the landscape of NSCLC using this newer technology and show its clinical utility in detecting known and novel facets of NSCLC to inform treatment decision-making.
Authors
- Pratheesh Sathyan
- Shakti Ramkissoon
- Eric A. Severson (ORCID: https://orcid.org/0000-0003-4394-2412)
- Erica Schnettler
- Hatim Husain (ORCID: https://orcid.org/0000-0003-4228-0963)
- Zachary D. Wallen (ORCID: https://orcid.org/0000-0002-2278-7348)
- Marcia Eisenberg
- Alison Roos
- Marni Brisson Tierno (ORCID: https://orcid.org/0000-0002-4159-0823)
- Brian Caveney
- Mary Nesline (ORCID: https://orcid.org/0000-0003-0523-4597)
Institutions
- Illumina (United States) (US)
- UC San Diego Health System (US)
- LabCorp (United States) (US)
- Wake Forest University (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.3389/fonc.2024.1473327
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42